Recent research from the US shows scientists have found that rare and aggressive neuroendocrine tumours shrink through a combination of two common immunotherapy drugs.
Research results were presented at the American Association for Cancer Research Annual Meeting 2019 and show a significant clinical benefit for patients with high-grade neuroendocrine carcinoma.
